Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CBARP divergent transcript (CBARP-DT) is an annotated long non-coding RNA (lncRNA) transcribed antisense to, and usually upstream from, the protein-coding CBARP gene. Such divergent transcripts are a genome-wide feature linked to the regulation of nearby genes, particularly at active promoters, but typically lack protein-coding potential and are not therapeutic targets themselves[2][4][1][5][6]. The biological function of CBARP-DT specifically is unknown, and there is no evidence of involvement in disease or druggability. More broadly, divergent transcripts can play a role in transcriptional regulation and the evolution of new genes, but most remain poorly characterized and have no direct therapeutic relevance[1][4][6].\nCBARP-DT appears in gene annotation databases as a lncRNA, not as a target for drug discovery, and there is no therapeutic, mechanistic, or disease linkage for this transcript in current scientific literature or database descriptions[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CBARP divergent transcript (CBARP-DT).